Custom Retatrutide CAS 2381089-83-2: Leading China Suppliers & Factory for Obesity and T2DM Treatment Solutions Manufacturer, Quotes
Product Description
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy.
Mechanism & Efficacy
Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.
Dosage & Research Use
Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.
What is Retatrutide?
Retatrutide is a novel triple receptor agonist that targets glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors.
What conditions is Retatrutide being researched for?
It is currently under active investigation in clinical and preclinical research primarily for the management of obesity and type 2 diabetes mellitus (T2DM).
How does Retatrutide work?
As a multi-agonist peptide, it is designed to enhance glucose regulation, promote significant weight loss, and support overall metabolic health.
Is Retatrutide FDA-approved?
No, Retatrutide is currently an investigational peptide in Phase 3 clinical trials and has not yet been FDA-approved for clinical use.
What dosages are being explored in clinical trials?
Trial protocols have explored once-weekly subcutaneous doses ranging from 1 mg up to 12 mg.
How is Retatrutide administered during these trials?
The dosage is often titrated over multiple 4-week intervals. This gradual increase is designed to balance the drug's efficacy with patient tolerability.
